Английская Википедия:Glycopyrronium bromide/formoterol

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Infobox drug

Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1][2] It is a combination of glycopyrronium bromide and formoterol. It is inhaled.[1][2]

The most common side effects include headache, nausea (feeling sick), muscle spasms and dizziness.[2]

Glycopyrronium bromide is a muscarinic receptor antagonist.[2] This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs.[2] Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.[2]

Formoterol is a long-acting beta-2 agonist.[2] It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways.[2] When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open.[2]

Medical uses

Glycopyrronium bromide/formoterol is indicated as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).[2]

History

Glycopyrronium bromide/formoterol was approved for medical use in the United States in April 2016,[3] and in the European Union in December 2018.[2]

It is marketed by AstraZeneca.[1][2]

References

Шаблон:Reflist

Further reading

External links

Шаблон:Drugs for obstructive airway diseases Шаблон:AstraZeneca Шаблон:Portal bar